Abstract 4131: MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression

Abstract

Abstract Nasopharyngeal carcinoma (NPC) is a common malignant cancer in Guangxi, as well as in southern China and Southeast Asia. NPC preferentially metastasizes to bone in advanced patients, major factor resulting in high mortality. The molecular basis of NPC development and cancer-induced bone lesions are still unclear. We and others have reported that chemokine, like CCL2, CXCL16, CXCL12, and their corresponding receptors played important roles in cancer bone metastasis. In this study, we firstly investigated that CCR2 and CXCR6 expressions in clinical specimens. Then, we measured CCL2, CCR2, CXCL16 and CXCR6 expression levels by RT-PCR, ELISA and western blot in NPC cell lines. Further, we used MEK inhibitor, U0126, to treat the NPC cell lines and found CCL2 and CXCL16 expressions significantly decreased. The NPC cell lines proliferation were inhibited by U0126 in dose- and time-dependently manner. Finally, we collected conditioned medium (CM) from the NPC cell lines absent or present U0126 treatments, to treat mouse bone marrow non-adherent cells in order to detect NPC CM-induced multinucleated osteoclast-like formation. The CMs collected from U0126 treated NPC cells were dramatically diminished the numbers of multinucleated osteoclasts. These results indicate that U0126 inhibits NPC cell growth and diminishes cancer-induced osteoclast formation partially through modulating the expression of CCL2 and CXCL16. Thus this study may provide a novel therapeutic strategy for advanced NPC patients, especially for treatment of NPC bone metastasis. Citation Format: Yu Zhu, Qiong Song, Yi Lu. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4131. doi:10.1158/1538-7445.AM2015-4131